Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers

Jordan, Karin; Kellner, O.; Kegel, Thomas; Schmoll, H.-J.; Grothey, Axel

doi:10.3816/ccc.2004.n.009

Cited by 32 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the availability of new effective agents for CRC came a host of new combination chemotherapy regimens, detailed in Table 1 unless otherwise specified [7][8][9][10][11][12][13][14][15][16][17][18][19][20]. Three key trials were conducted in metastatic CRC and published in 2000 [9][10][11].…”

Section: Developing the Current Standard Of Carementioning

confidence: 99%

“…The efficacy of capecitabine combined with either irinotecan (XELIRI) or oxaliplatin (XELOX) has been demonstrated in a multitude of phase II trials, with response rates of 55% (XELOX) and 44% (XELIRI) and median TTP of 7.6 months (XELOX) and 6.7 months (XELIRI) [17,20]. A phase III comparison trial of the two similar regimens, CAPOX and CAPIRI, is under way [19]. Trials comparing capecitabine with 5-FU-containing regimens with either oxaliplatin or irinotecan are also ongoing.…”

Section: Improving the Current Standard Of Carementioning

confidence: 99%

See 1 more Smart Citation

Advances in the Treatment of Metastatic Colorectal Cancer

Goldberg

2005

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Identify the advantages and disadvantages of the various chemotherapeutic regimens used to treat metastatic colorectal cancer.2. Discuss the emerging role of new agents for the treatment of metastatic colorectal cancer.3. Discuss the current status of trials of new combination therapies in the treatment of metastatic colorectal cancer.4. Describe quality of life data for combination chemotherapy for metastatic colorectal cancer and the influence of quality of life on treatment decisions.

show abstract

Section: Developing the Current Standard Of Carementioning

confidence: 99%

Section: Improving the Current Standard Of Carementioning

confidence: 99%

Advances in the Treatment of Metastatic Colorectal Cancer

Goldberg

2005

The Oncologist

View full text Add to dashboard Cite

show abstract

“…An 88-year-old woman of Sicilian origin presented with nausea, vomiting and diarrhoea seven days after completion of her first cycle of chemotherapy for colon cancer with capecitabine and irinotecan [5]. Colorectal cancer was diagnosed as pT4, N2, Mx, R1, V1, L1 about a year before and was initially treated with capecitabine monotherapy until the disease progressed.…”

mentioning

confidence: 99%

Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report

et al. 2010

View full text Add to dashboard Cite

“…(LV5FU2) in combination schedules of oxaliplatin and irinotecan (Cassidy et al, 2004;Jordan et al, 2004).…”

mentioning

confidence: 99%

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

et al. 2005

View full text Add to dashboard Cite

Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer. Owing to potential synergy based upon upregulation of thymidine phosphorylase by MMC, the combination of capecitabine and MMC may improve outcomes in irinotecan-refractory disease. Eligible patients with progressive disease during or within 6 months of second-line chemotherapy were treated with capecitabine (1250 mg m À2 twice daily) days 1-14 every 3 weeks and MMC (7 mg m À2 IV bolus) once every 6 weeks. A total of 36 patients were recruited, with a median age of 64 years (range 40 -77), and 23 patients (78%) were performance status 0 -1. The objective response rate was 15.2%. In all, 48.5% of patients had stable disease. Median failure-free survival was 5.4 months (95% CI 4.6 -6.2). Median overall survival was 9.3 months (95% CI: 6.9 -11.7). Grade 3 toxicities were palmar-plantar erythema 16.7%, vomiting 8.3%, diarrhoea 2.8%, anaemia 8.3%, and neutropenia 2.8%. No patients developed haemolytic uraemic syndrome. Symptomatic improvement occurred for pain, bowel symptoms, and dyspnoea. Capecitabine in combination with MMC is an effective regimen for metastatic colorectal cancer resistant to 5FU and irinotecan with an acceptable toxicity profile and a convenient administration schedule.

show abstract

Phase II Trial of Capecitabine/Irinotecan and Capecitabine/Oxaliplatin in Advanced Gastrointestinal Cancers

Cited by 32 publications

References 17 publications

Advances in the Treatment of Metastatic Colorectal Cancer

Advances in the Treatment of Metastatic Colorectal Cancer

Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

Contact Info

Product

Resources

About